A Phase 4 interventional study of spinosad in Pediculosis, sponsored by ParaPRO LLC. Completed at 2 sites in United States. Open to participants aged 6 Months to 4 Years. Per ClinicalTrials.gov, last updated 2012-11-22.
Sponsored by ParaPRO LLC · Phase 4, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Lice Infestations with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Lice Infestations · United States.
Among the 25 studies in Lice Infestations with a site in United States, this one is the 21st largest by enrollment, is one of 3 that started in 2011, is one of 2 in phase 4, and was the 16th registered.
43 studies on the registry are indexed under Lice Infestations; 4 are open to participants now.
Browse Lice Infestations studies →1 of the 25 studies in Lice Infestations with a site in United States is open now. Recruiting first, the newest first:
Oystershell NV · Sites in United States
Ages 1+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Lice Infestations studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 6 Months to 4 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 7 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 105 across 42 interventional studies indexed under Lice Infestations.
Median enrollment 98 across the 25 interventional studies. Of the 23 that completed or were terminated, 13 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 25 have an industry lead sponsor. The 9 most frequent:
ParaPRO LLC is the lead sponsor of 11 studies on the registry; none are open to participants now.
ParaPRO LLC has 6 studies filed under Lice Infestations — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Lice Infestations with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A pharmacokinetic and tolerance study of Natroba (spinosad) Topical Suspension, 0.9% in pediatric subjects 6 months to 4 years of age with an active head lice infestation.
A Postmarketing Requirement Protocol, multicenter, open-label study in pediatric subjects 6 months to 4 years of age with an active head lice infestation designed to determine the topical absorption and safety of Natroba (spinosad) Topical Suspension, 0.9% for a single, 10 minute treatment for spinosad (Spinosyn A and Spinosyn D) and benzyl alcohol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Natroba (Spinosad) Topical Suspension, 0.9%
Drug: spinosad
A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.
Also known as: Natroba (spinosad) Topical Suspension, 0.9%
Cmax for Spinosyn A
Peak Plasma Concentration of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9%
Time frame: Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.
Tmax for Spinosyn A
The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn A.
Time frame: Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.
AUC (0-12) for Spinosyn A
Area under the plasma concentration versus time curve (AUC) of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9%.
Time frame: Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.
Cmax for Spinosyn D
Peak Plasma Concentration of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9%
Time frame: Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.
Tmax for Spinosyn D
The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn D.
Time frame: Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.
AUC (0-12) for Spinosyn D
Area under the plasma concentration versus time curve (AUC) of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9%.
Time frame: Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.
Cmax for Benzyl Alcohol
Peak Plasma Concentration of benzyl alcohol (above Limit of Quantitation (1.0 μg/mL) in Natroba (spinosad) Topical Suspension, 0.9%.
Time frame: Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.
Tmax for Benzyl Alcohol
The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for benzyl alcohol.
Time frame: Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.
AUC (0-12) for Benzyl Alcohol
Area under the plasma concentration versus time curve (AUC) of benzyl alcohol in Natroba (spinosad) Topical Suspension, 0.9%.
Time frame: Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.
Overall Study
| Milestone | Natroba |
|---|---|
| Started | 26 |
| Completed | 26 |
| Not completed | 0 |
Peak Plasma Concentration of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9%
| ng/mL | Natroba |
|---|---|
| Cmax for Spinosyn A | NA |
The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn A.
| hours | Natroba |
|---|---|
| Tmax for Spinosyn A | NA |
Area under the plasma concentration versus time curve (AUC) of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9%.
| ng*hr/mL | Natroba |
|---|---|
| AUC (0-12) for Spinosyn A | NA |
Peak Plasma Concentration of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9%
| ng/mL | Natroba |
|---|---|
| Cmax for Spinosyn D | NA |
The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn D.
| hours | Natroba |
|---|---|
| Tmax for Spinosyn D | NA |
Area under the plasma concentration versus time curve (AUC) of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9%.
| ng* hr/mL | Natroba |
|---|---|
| AUC (0-12) for Spinosyn D | NA |
Peak Plasma Concentration of benzyl alcohol (above Limit of Quantitation (1.0 μg/mL) in Natroba (spinosad) Topical Suspension, 0.9%.
| μg/mL | Natroba |
|---|---|
| Cmax for Benzyl Alcohol | 1.123 ± 0.3071 |
The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for benzyl alcohol.
| hours | Natroba |
|---|---|
| Tmax for Benzyl Alcohol | 0.5 ± 0.3071 |
Area under the plasma concentration versus time curve (AUC) of benzyl alcohol in Natroba (spinosad) Topical Suspension, 0.9%.
| μg*hr/mL | Natroba |
|---|---|
| AUC (0-12) for Benzyl Alcohol | NA |
Collected over Throughout the study.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Natroba | — | 0/26 (0%) | 9/26 (34.6%) |
| Event | Natroba |
|---|---|
| PyrexiaGeneral disorders | 7/26 |
| Application Site PruritusGeneral disorders | 3/26 |
| PruritusSkin and subcutaneous tissue disorders | 2/26 |
| ErythemaSkin and subcutaneous tissue disorders | 1/26 |
| Age, Categorical(Participants) | Natroba |
|---|---|
| <=18 years | 26 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age Continuous(years) | Natroba |
|---|---|
| Mean | 2 ± 0.9 |
| Sex: Female, Male(Participants) | Natroba |
|---|---|
| Female | 11 |
| Male | 15 |
| Region of Enrollment(participants) | Natroba |
|---|---|
| United States | 26 |
The record gives a start of Sep 2011, a primary completion of Oct 2011 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Spinosad
ParaPRO LLC